BRISTOL-MYERS SQUIBB COMPANY (BMY) Share buybacks
- Total buybacks · last 12 months (USD): Value $0.00; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2025-12-31..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2025-12-31..
Share buybacks
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $0.00 | Trailing-year cash paid for share repurchases. Period ending 2025-12-31. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 0.00 USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2025-12-31 | $0.00 | (m) | (m) |
| 2024-12-31 | $0.00 | (m) | (m) |
| 2024-09-30 | $0.00 | (m) | (m) |
| 2024-06-30 | $4.00B | (m) | (m) |
| 2024-03-31 | $4.91B | (m) | (m) |
| 2023-12-31 | $5.16B | (m) | (m) |
| 2023-09-30 | $7.57B | (m) | (m) |
| 2023-06-30 | $4.16B | (m) | (m) |
| 2023-03-31 | $3.25B | (m) | (m) |
| 2022-12-31 | $8.00B | (m) | (m) |
| 2022-09-30 | $8.34B | (m) | (m) |
| 2022-06-30 | $8.28B | (m) | (m) |
| 2022-03-31 | $9.51B | (m) | (m) |
| 2021-12-31 | $6.29B | (m) | (m) |
| 2021-09-30 | $5.00B | (m) | (m) |
| 2021-06-30 | $4.48B | (m) | (m) |
| 2021-03-31 | $3.24B | (m) | (m) |
| 2020-12-31 | $1.55B | (m) | (m) |
| 2020-09-30 | $7.08B | (m) | (m) |
| 2020-06-30 | $7.38B | (m) | (m) |
| 2020-03-31 | $7.38B | (m) | (m) |
| 2019-12-31 | $7.30B | (m) | (m) |
| 2019-09-30 | $300.00M | (m) | (m) |
| 2019-06-30 | $0.00 | (m) | (m) |
| 2019-03-31 | $153.00M | (m) | (m) |
| 2018-12-31 | $320.00M | (m) | (m) |
| 2018-09-30 | $569.00M | (m) | (m) |
| 2018-06-30 | $789.00M | (m) | (m) |
| 2018-03-31 | $636.00M | (m) | (m) |
| 2017-12-31 | $2.47B | (m) | (m) |
| 2017-09-30 | $2.22B | (m) | (m) |
| 2017-06-30 | $2.00B | (m) | (m) |
| 2017-03-31 | $2.00B | (m) | (m) |
| 2016-12-31 | $231.00M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) |
| 2013-12-31 | $433.00M | (m) | (m) |
| 2013-09-30 | $925.00M | (m) | (m) |
| 2013-06-30 | $1.92B | (m) | (m) |
| 2013-03-31 | $2.36B | (m) | (m) |
| 2012-12-31 | $2.40B | (m) | (m) |
| 2012-09-30 | $2.27B | (m) | (m) |
| 2012-06-30 | $1.70B | (m) | (m) |
| 2012-03-31 | $1.41B | (m) | (m) |
| 2011-12-31 | $1.22B | (m) | (m) |
| 2011-09-30 | $1.08B | (m) | (m) |
| 2011-06-30 | $796.00M | (m) | (m) |
| 2011-03-31 | $724.00M | (m) | (m) |
| 2010-12-31 | $576.00M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |